Metastatic Renal Cell Cancer Treated With Antiangiogenic Therapy Monitoring by F-18-FDG PET/CT

摘要

Renal cell carcinoma (RCC) is resistant to chemotherapy and radiotherapy in most cases, and surgery is the preferred option in patients with local tough advanced disease. Even in metastatic RCC, patient survival has been reported to improve after surgery. Considering the importance of angiogenesis in RCC pathogenesis, new inhibitors of vascular endothelial growth factor pathway show promising results. Imaging monitoring with F-18-FDG PET/CT may allow selecting the appropriateness and right time to implement these drugs, according to disease outcome.